The Federal Register http://thefederalregister.com/b.p/department/DEPARTMENT_OF_JUSTICE/2003-12-02/ Daily Publications of Meetings and Rules Changes for the Federal Government Fri, Dec 5 2008 11:00:00 GMT Fri, Dec 5 2008 11:00:00 GMT info@thefederalregister.com <![CDATA[ Importation of Controlled Substances; Notice of Application]]> http://thefederalregister.com/d.p/2003-12-02-03-29964

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule II and prior to issuing a registration under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registration for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on May 30, 2003, Abbott Laboratories, 1776 North Centennial Drive, McPherson, Kansas 674601247, made application by renewal to the Drug Enforcement Administration to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in Schedule II.

The firm plans to import the remifentanil to manufacture a controlled substance for distribution to its customers.

Any manufacturer ]]> http://thefederalregister.com/d.p/2003-12-02-03-29964 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29976

By Notice dated August 19, 2003, and published in the Federal Register on September 2, 2003, (68 FR 52224), American Radiolabeled Chemical, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Gamma Hydroxybutyric Acid (2010)........... I
Lysergic acid diethylamide (7315).......... I
Dimethyltryptamine (7435).................. I
Dihydromorphine (9145)..................... I
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Morphine (9 ]]> http://thefederalregister.com/d.p/2003-12-02-03-29976 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29974

By Notice dated August 19, 2003, and published in the Federal Register on September 2, 2003, (68 FR 52224), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration for registration as a bulk manufacturer of Dextropropoxyphene (9273), a basic class of Schedule II controlled substance.

The firm plans to manufacture bulk controlled substances for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the regulation of Cambrex Charles City, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the ]]> http://thefederalregister.com/d.p/2003-12-02-03-29974 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Importer of Controlled Substances; Notice of Registration ]]> http://thefederalregister.com/d.p/2003-12-02-03-29971

By Notice dated June 25, 2003 and published in the Federal Register on July 14, 2003, (68 FR 41661), Cambrex North Brunswick, Inc., Technology Center of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The firm plans to import the listed controlled substance to manufacture amphetamine.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Cambrex North Brunswick, Inc. to import the listed controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Cambrex North Brunswick, Inc. on a regular basis to ensure that the company's ]]> http://thefederalregister.com/d.p/2003-12-02-03-29971 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29972

By Notice dated June 25, 2003, and published in the Federal Register on July 14, 2003, (68 FR 41661), Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule NEthylamphetamine (1475).................. I
Tetrahydrocannabinols (7370)............... I
2,5Dimethoxyamphetamine (7396)............ I
3,4Methylenedioxyamphetamine (7400)....... I
4Methoxyamphetamine (7411)................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Morphine (9300)............................ II

Fentanyl (9801)............................ II

The firm plans to manufacture the listed controlled substances for distribution to its cu ]]> http://thefederalregister.com/d.p/2003-12-02-03-29972 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29977

By Notice dated August 19, 2003, and published in the Federal Register on September 2, 2003, (68 FR 52224), Cambridge Isotope Laboratories, Inc., 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Methaqualone (2565)........................ I
Dimethyltryptamine (7435................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Pentobarbital (2270)....................... II
Secobartbital (2315)....................... II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Methadone (9250 ]]> http://thefederalregister.com/d.p/2003-12-02-03-29977 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Anthony D. Dinozzi, D.D.S., Revocation of Registration ]]> http://thefederalregister.com/d.p/2003-12-02-03-29966

On September 25, 2002, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Anthony David Dinozzi, D.D.S. (Respondent) notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificate of Registration, BD4361692 under 21 U.S.C. 824(a)(2), (a)(3), and (a)(4). The Order to Show Cause further sought to deny any pending applications for renewal or modification of the Repsondent's registration for reasons that he was convicted of a felony offense related to controlled substances, is not authorized to handle controlled substances, and his continued registration would be inconsistent with the public interest.

Specifically, the Order to Show alleged that the Respondent is not authorized under state law to handle controlled substances based upon the March 31, 2001, expiration of his Pennsylvania state license to practice dentistry. The Order to Show Cause further alleged that the R ]]> http://thefederalregister.com/d.p/2003-12-02-03-29966 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Application]]> http://thefederalregister.com/d.p/2003-12-02-03-29961

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 25,
[[Page 67476]]
2003, Lifepoint, Inc., 10400 Trademark Street, Rancho Cucamonga, California 91730, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Tetrahydrocannabinols (7370)............... I
3,4Methylenedioxyamphetamine (7400)....... I
3,4MethylenedioxyNethylamphetamine I
(7404).
3,4Methylenedioxymethamphetamine (7405)... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
phencyclidine (7471)....................... II
Benzoylecogonine (9180).................... II

Morphine (9300)............................ II

The firm plans to produce small quantities of controlled substances for use in drug test kits.

Any other such applicant a ]]> http://thefederalregister.com/d.p/2003-12-02-03-29961 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29975

By Notice dated August 19, 2003, and published in the Federal Register on September 2, 2003, (68 FR 52225), LinZhi International, Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Tetrahydrocannabinols (7370)............... I
3,4Methylenedioxymethamphetamine (7405)... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Secobarbital (2315)........................ II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Methadone (9250)........................... II
Dextropropoxyphene (9273).................. II

Morphine (9300)............................ II

The firm plans to manufacture small quantities of controlled substances to make drug testing reagents and controls.
]]> http://thefederalregister.com/d.p/2003-12-02-03-29975 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Jules M. Lusman, M.D., Revocation of Registration ]]> http://thefederalregister.com/d.p/2003-12-02-03-29967

On September 6, 2002, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Jules Lusman, M.D. (Respondent) notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificate of Registration, BL2210300 under 21 U.S.C. 824(a)(3) and (a)(4). The Order to Show Cause alleged that the Respondent's DEA Certificate of Registration should be revoked because the Respondent was without authorization to handle controlled substances. The Order to Show Cause further sought denial of any pending applications for registration based on allegations that the Respondent's continued registration would be inconsistent with the public interest. Specifically, the Order to Show alleged that effective March 15, 2002, the California Medical Board (Medical Board) ordered that Respondent be prohibited from handling controlled substances based upon acts of negligence in both his care of patients and billing ]]> http://thefederalregister.com/d.p/2003-12-02-03-29967 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Application]]> http://thefederalregister.com/d.p/2003-12-02-03-29962

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 11, 2003 and September 18, 2003, National Center for Development of Natural Products, The University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Marihuana (7360)........................... I

Tetrahydrocannabinols (7370)............... I

The firm plans to bulk manufacture for product development.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the Proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion ]]> http://thefederalregister.com/d.p/2003-12-02-03-29962 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Importer of Controlled Substances; Notice of Registration ]]> http://thefederalregister.com/d.p/2003-12-02-03-29968

By Notice dated July 2, 2003 and published in the Federal Register on July 21, 2003, (68 FR 431650, Noramco Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed below:] [[Page 67478]]
Drug Schedule Opium, (raw) (9600)........................ II

Poppy Straw Concentrate (9670)............. II

The firm plans to import the listed controlled substances to bulk manufacture other controlled substances.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Noramco Inc. to import the listed controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at th ]]> http://thefederalregister.com/d.p/2003-12-02-03-29968 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29973

By Notice dated June 25, 2003, and published in the Federal Register on July 14, 2003, (68 FR 41663), Novus Fine Chemicals, LLC, 611 Broad Street, Carlstadt, New Jersey 07072, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic class of Methylphenidate (1724), a Schedule II controlled substance.

The firm plans to manufacture bulk Methylphenidate to distribute to its customers for the manufacture of finished products.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Novus Fine Chemicals, LLC, to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Novus Fine Chemicals, LLC, to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical securi ]]> http://thefederalregister.com/d.p/2003-12-02-03-29973 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29969

By Notice dated July 22, 2003, and published in the Federal Register on August 5, 2003, (68 FR 46226), Penick, Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II

Oxymorphone (9652)......................... II

The firm plans to manufacture controlled substances and non controlled flavo ]]> http://thefederalregister.com/d.p/2003-12-02-03-29969 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Keith Perry, M.D. Revocation of Registration ]]> http://thefederalregister.com/d.p/2003-12-02-03-29965

On October 17, 2002, the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Keith O'Neil Perry, M.D. (Respondent) notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificate of Registration, AP3109077 under 21 U.S.C. 824(a)(3) and (a)(4), and deny any pending applications for registration pursuant to 21 U.S.C. 823(f). The Order to Show Cause alleged that the Respondent's DEA Certificate of Registration should be revoked because the Respondent was without authorization to handle controlled substances. The Order to Show Cause further sought denial of any pending applications for registration based on allegations that the Respondent's continued registration would be inconsistent with the public interest. Specifically, the Order to Show alleged that effective April 8, 2002, the California Medical Board (Medical Board) suspended the Respondent's license to practice medicine. Th ]]> http://thefederalregister.com/d.p/2003-12-02-03-29965 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances; Notice of Application]]> http://thefederalregister.com/d.p/2003-12-02-03-29963

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on September 18, 2003, Sigma Aldrich Research Biochemicals, Inc., 13 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Alphaethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4Bromo2,5dimethoxyamphetamine (7391)... I
4Bromo2,5dimethoxyphenethylamine (7392). I
2,5Dimethoxyamphetamine (7396)............ I
3,4Methylenedioxyamphetamine (7400)....... I
NHydroxy3,4methylenedioxyamphetamine I
(7402).
3,4MethylenedioxyNethylamphetamine I ]]> http://thefederalregister.com/d.p/2003-12-02-03-29963 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Importation of Controlled Substances; Notice of Application]]> http://thefederalregister.com/d.p/2003-12-02-03-29960

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on February 11, 2003, Stepan Company, Natural Products Dept, 100 W. Hunter Avenue, Maywood, new Jersey 07607, made application by renewal to the Drug Enforcement Administration to be registered as an importer of Coca Leaves (9040), a basic class of controlled substance listed in Schedule II.

The firm plans to import the coca leaves to manufacture bulk controlled substances.

Any manufacturer holding, or applyi ]]> http://thefederalregister.com/d.p/2003-12-02-03-29960 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Manufacturer of Controlled Substances, Notice of Registration]]> http://thefederalregister.com/d.p/2003-12-02-03-29970

By Notice dated July 22, 2003, and published in the Federal Register on August 5, 2003, (68 FR 46227), Wildlife Laboratories, Inc., 1401 Duff Drive, Suite 600, Fort Collins, Colorado 80524, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of Carfentanil (9743), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture the listed controlled substance for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Wildlife Laboratories, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Wildlife Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security syste ]]> http://thefederalregister.com/d.p/2003-12-02-03-29970 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Agency Information Collection Activities: Proposed Collection; Comments Requested]]> http://thefederalregister.com/d.p/2003-12-02-03-29913

The Department of Justice (DOJ), Office of Justice Programs (OJP) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 68, Number 167, page 51805 on August 27, 2003, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until January 2, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of J ]]> http://thefederalregister.com/d.p/2003-12-02-03-29913 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Agency Information Collection Activities: Proposed Collection; Comments Requested]]> http://thefederalregister.com/d.p/2003-12-02-03-29914

The Department of Justice (DOJ), Office of Justice Programs (OJP) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 68, Number 167, page 51806 on August 28, 2003, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until January 2, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Off ]]> http://thefederalregister.com/d.p/2003-12-02-03-29914 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Agency Information Collection Activities: Proposed Collection; Comments Requested]]> http://thefederalregister.com/d.p/2003-12-02-03-29915

The Department of Justice (DOJ), Office of Justice Programs (OJP) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 68, Number 167, page 51805 on August 28, 2003, allowing for a 60day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until January 2, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Offi ]]> http://thefederalregister.com/d.p/2003-12-02-03-29915 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Agency Information Collection Activities: Proposed Collection; Comments Requested]]> http://thefederalregister.com/d.p/2003-12-02-03-29916

The Department of Justice (DOJ), Office of Justice Programs (OJP) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 68, Number 167, page 51807 on August 28, 2003, allowing for a 60day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until January 2, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to The Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Offi ]]> http://thefederalregister.com/d.p/2003-12-02-03-29916 Tue, Dec 2 2003 11:00:00 GMT <![CDATA[ Agency Information Collection Activities: Proposed Collection; Comment Request]]> http://thefederalregister.com/d.p/2003-12-02-03-29917

The Department of Justice (DOJ), Office of Justice Programs (OJP) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the Federal Register Volume 68, Number 108, page 33745 on June 5, 2003, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until January 2, 2004. This process is conducted in accordance with 5 CFR 1320.10.

Written comments, or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention: Department of Justice D ]]> http://thefederalregister.com/d.p/2003-12-02-03-29917 Tue, Dec 2 2003 11:00:00 GMT